Concepedia

Author

Paula J. Andryuk

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

P J Andryuk, P. J. Andryuk, Paula J. Andryuk

6

Publications

1.1K

Citations

6

H-Index

16

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Dallas Diabetes Research Center
PJ

About

Paula J. Andryuk is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, genetics, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

712

2

Cell Biology

2

2

199

3

Natural Sciences

1

1

111

4

Diabetes

1

1

513

5

Immunology

1

1

111

Paula J. Andryuk

×

6

Publications

1.1K

Citations

6

H-Index

YearCitations

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Julio Rosenstock, Ronald Brazg, Paula J. Andryuk,

Clinical Therapeutics

2006

513

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Tina Vilsbøll, Julio Rosenstock, H Yki-Järvinen,

Diabetes Obesity and Metabolism

2009

303

Three distinct human thymopoietins are derived from alternatively spliced mRNAs.

Crafford A. Harris, Paula J. Andryuk, Scott W. Cline,

Proceedings of the National Academy of Sciences

1994

111

Structure and Mapping of the Human Thymopoietin (TMPO) Gene and Relationship of Human TMPO β to Rat Lamin-Associated Polypeptide 2

Crafford A. Harris, Paula J. Andryuk, Scott W. Cline,

Genomics

1995

88

Glucagon receptor antagonism induces increased cholesterol absorption

Hong-Ping Guan, Xiaodong Yang, Ku Lu,

Journal of Lipid Research

2015

76

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( <scp>DPP</scp> ‐4) inhibitor omarigliptin or the once‐daily <scp>DPP</scp> ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Ronald Goldenberg, Ira Gantz, Paula J. Andryuk,

Diabetes Obesity and Metabolism

2017

30

Page 1